Navigation Links
ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results
Date:8/12/2009

related to ANX-514, a $0.2 million decrease in non-clinical expenses related to ANX-201 and ANX-211, a $0.2 million decrease in non-clinical expenses related to ANX-530, a $1.1 million decrease in personnel costs and a $0.5 million decrease in share-based compensation expense, offset by a $0.1 million increase in external clinical trial expenses related to ANX-514.

SG&A expenses in the first half of 2009 were $2.9 million, a decrease of $2.2 million, or 43%, compared with SG&A expenses of $5.0 million in the first half of 2008. The decrease was primarily due to a $1.1 million decrease in personnel costs, a $0.3 million decrease related to share-based compensation expense, a $0.4 million decrease in legal and professional services, a $0.1 million decrease in market research expenses, a $0.2 million decrease in travel expenses, and a $0.1 million decrease in insurance related expenses.

Balance Sheet Highlights


As of June 30, 2009, the Company had cash and cash equivalents of $5.4 million and stockholders' equity of $2.3 million.

Conference Call and Webcast

ADVENTRX will hold a conference call today beginning at 4:30 p.m. Eastern time to review financial results for the second quarter and provide an update on its business. Individuals interested in listening to the conference call may do so by dialing (866) 305-6438 for domestic callers, or (706) 679-7161 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.adventrx.com. A 48-hour telephone replay will be available approximately one hour after the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 23355569. The webcast will be available on the Company's Web site for 14 days following the completion of the call.

About ADVENTRX Ph
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Announces Consolidation of Clinical and Management Positions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a commercial focus on China , ... (CFDA) has approved the Company,s application to conduct a ... carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)...    Intrexon Corporation (NYSE: XON ... Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, ... exclusive strategic collaboration and license agreement to develop ... therapies. This collaboration advances Merck Serono,s comprehensive, science-driven ... immune system,s natural ability to fight tumors. ...
(Date:3/30/2015)... UK, and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... projects in Europe and the United States and plenary ... highlights planned for SPIE Optics + Optoelectronics ... feature over 700 technical presentations in 17 conferences alongside ... society for optics and photonics , the event will ...
(Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
... David B. Samadi, M.D., a world renowned urologic oncologist, discusses his ... techniques spare nerves, tissues, and organs responsible for sexual function and ... surgeries and the results are quite pleasing for his patients. ... ...
... study of Global Methylation with results in half the time ... ... ST. LOUIS, Oct. 30 Sigma-Aldrich (Nasdaq:,SIAL) today introduced ... http://www.sigma-aldrich.com/mdq1 . The,Methylated DNA Quantification Kit employs a familiar ELISA-like ...
... the National Institute of Standards and Technology ... to quickly and cheaply analyze nanoscale dimensions ... Optical Microscope (TSOM) imaging, the technique has ... and biotechnology. , Optical microscopes are not ...
Cached Biology Technology:Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast 2Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast 3Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast 4Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research 2Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research 3Nanoscale dimensioning is fast, cheap with new NIST optical technique 2
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... that an investigational drug (R207910, currently in clinical ... effective at killing latent bacteria. This revelation ... shortened treatments for this globally prevalent disease. ... a serious disease fueled by co-infection of HIV ...
... Fairbanks, Alaska More than 150 scientists are expected to ... of Science Arctic Division conference in Fairbanks, Alaska Sept. ... science and the people of the Arctic. Sessions ... continuing changes in northern regions, as well as on ...
... The chairman of EUS2008 today announced that investigational ... physicians to directly inject malignant tumors with cancer ... presented at the 16th International Symposium of Endoscopic ... This technique, which uses a flexible gastrointestinal endoscope ...
Cached Biology News:Anti-tumor therapy with endoscopic ultrasound may fight cancer more safely and effectively 2
The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
... Incubated Orbital Shakers combine high durability ... and ease of use. The patented ... the unit to run at high ... unit's class-leading temperature range is delivered ...
Small bottle for hybridization 150 x 35mm...
Biology Products: